Arthritis Wonder Drugs Provide Clues for All Diseases
Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis – a leading cause of heart disease – says the researcher who jointly invented and developed them.
Professor Marc Feldmann will tell scientists attending the 2008 Congress of European Pharmacological Societies (EPHAR) that biologics have already proved successful against other autoimmune diseases.
"We … found that by blocking just one cytokine – tumor necrosis factor (TNF)-alpha – we were able to block all the cytokines involved in the inflammation, with remarkable clinical results."
The team's research led to the development of three anti-TNF-alpha drugs – infliximab, etanercept and adalimumab – which have had a dramatic effect on the symptoms of rheumatoid arthritis, protecting the joints from further deterioration in the vast majority of cases.
Blocking TNF-alpha has had additional success in treating several more chronic inflammatory conditions, including Crohn's disease, psoriasis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
But Professor Feldmann, Head of the Kennedy Institute of Rheumatology, believes similar drugs have the potential to treat many other medical conditions and will also tell the conference about his work on atherosclerosis, a disease affecting the arterial blood vessels, commonly known as 'hardening of the arteries', with his colleague Dr. Claudia Monaco.
Their work, which has won a number of prestigious awards, has resulted in the emergence of a new branch of medicine – anti-cytokine therapy.
Professor Feldmann said: "During the conference I will be discussing the potential therapeutic targets in tissue affected by atherosclerosis, which is caused by a chronic inflammatory response in the walls of the arteries, in large part, caused by an excessive immune response to cholesterol.
"I will also discuss whether it is possible – even likely – that cytokines play a critical role in all diseases involving multiple biological processes, thus providing therapeutic targets for all unmet medical needs."
This article was adapted from a press release issued by University of Manchester.
